Cytokinetics, Incorporated · NASDAQ:CYTK
Cytokinetics — Investor Presentation (March 2026)
60 slides from Cytokinetics's investor presentation, March 2026
Slide 1: Cytokinetics
G . Cytokinetics’
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe ha
Slide 3: Our Mission
Our Mission To bring forward new medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. 3
Slide 4: Now Available
Now Available FDA-approved for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms FDA: U.S. Food & Drug Administration; oHCM: obstructive hypertrophic cardiomyopathy Please see full Prescribing Information, including Boxed WARNING and Medication Guide 4
Slide 5: A Commitment to Muscle-Directed Cardiac Medicines
A Commitment to Muscle-Directed Cardiac Medicines Drug Therapeutic Area Candidate (Clinical Trial) Research Pre-Clinical Phase 1 Phase 2 Phase 3 Commercialized oHCM Approved Aficamten in US, China & EU* SEQUOIA-HCM oHCM (vs. metoprolol) sNDA submitted Aficamten in Q1 '26 MAPLE-HCM Pediatric oHCM Afi
Slide 6: Positioned for Launch Velocity & Sustainable Growth
Positioned for Launch Velocity & Sustainable Growth COMMERCIAL RESEARCH & DEVELOPMENT STRONG FINANCIAL POSITION Specialty Muscle-directed platform with multi-program pipeline Cardiology ~$1.22B Franchise cash & cash equivalents (as of 12/31/25) sNDA for aficamten submitted in Q1 2026 Access to furth
Slide 7: Vision 2030: Innovation, Ignition, Impact
INNOVATION Advance 2 approved products across 3 indications and 10 NMEs in our pipeline IGNITION Achieve broad access and rapid use of our medicines in >15 countries throughout North America and Europe IMPACT Reach >100,000 patients globally with our medicines INSPIRATION Foster a patient-centric cu
Slide 8: Building a Specialty Cardiology Franchise
Building a Specialty Cardiology Franchise 8
Slide 9: Building Specialty Cardiology Business for High ROI
Building Specialty Cardiology Business for High ROI Concentrated Prescribers Higher Revenue Per Prescriber Opportunity To Grow ~80K cardiologists/PCPs treat CV diseases Market Through Diagnosis ~10K $$$$/ 50 % cardiologists HCP treat ~80% HCM $/HCP General Specialty Distribution Limited to Different
Slide 10: Addressing Difficult to Treat Populations Within Heart Failure
Addressing Difficult to Treat Populations Within Heart Failure Specialty cardiology franchise strategy applies to markets with similar characteristics HFrEF HFpEF HCM Severely Supranormal EF reduced EF Opportunity for MYQORZO Addressing underserved segment Expanding into adjacent population* (aficam
Slide 11: Potential for Multiple Specialty Cardiology Launches
Potential for Multiple Specialty Cardiology Launches Drug Potential Candidate Indication 2024 2025 2026 2027 2028 2029 2030+ oHCM MYQORZO oHCM Mono (aficamten) (MAPLE-HCM) nHCM (ACACIA-HCM) Omecamtiv HFrEF Mecarbil Ulacamten HFpEF Estimated date of potential future launch of each candidate for the r
Slide 12: MYQORZO (aficamten): Clinical Evidence
MYQORZO (aficamten) Clinical Evidence Prescribing Information Medication Guide 12
Slide 13: About oHCM
About oHCM Left Ventricular Outflow Tract (LVOT) • HCM causes the heart muscle to abnormally thicken. • In obstructive HCM (oHCM), the thickened muscle causes the left ventricle to become smaller, stiffer and less able to relax and fill with blood.1–4 • In oHCM, obstruction of the LVOT, blocks blood
Slide 14: MYQORZO Inhibits Cardiac Myosin Motor Activity
MYQORZO Inhibits Cardiac Myosin Motor Activity oHCM causes cardiac MYQORZO binds to and hypercontractility, inhibits cardiac myosin, impaired cardiac relaxation & reducing cardiac contractility increased energy consumption & LVOT obstruction MYQORZO Actin Active myosin head Deactivated myosin head o
Slide 15: SEQUOIA-HCM: Pivotal Phase 3 Trial
SEQUOIA-HCM: Pivotal Phase 3 Trial Primary endpoint: Change in pVO2 by CPET from baseline to Week 24 Randomization Aficamten + SoC End of Study Patients with Screening oHCM treated Secondary objectives include measuring with SOC with post-Valsalva 1 change in KCCQ & improvement in peak LVOT-G ≥50 mm
Slide 16: SEQUOIA-HCM: Pivotal Phase 3 Trial in oHCM
SEQUOIA-HCM: Pivotal Phase 3 Trial in oHCM Significant improvement in exercise capacity and symptoms compared to placebo Treatment with MYQORZO for 24 weeks also significantly improved: Gradients -50 mmHg placebo-corrected change in post-Valsalva LVOT-G (p<0.0001)1 Absolute Change from Baseline to W
Slide 17: SEQUOIA-HCM: Safety Data
SEQUOIA-HCM: Safety Data MYQORZO Placebo Event, n (%) (n=142) (n=140) Overall AEs 105 (73.9) 99 (70.7) Headache 11 (7.7) 10 (7.1) Hypertension 11 (7.7) 3 (2.1) Palpitations 10 (7.0) 4 (2.9) AEs with ≥5% incidence Upper respiratory infection 9 (6.3) 12 (8.6) COVID-19 8 (5.6) 9 (6.4) There were no ser
Slide 18: MAPLE-HCM: Phase 3 Monotherapy Trial in oHCM
MAPLE-HCM: Phase 3 Monotherapy Trial in oHCM Aficamten superior to standard-of-care beta blocker metoprolol Relative to metoprolol, aficamten also improved: Gradients Mean Change from Baseline to Week 24 in pVO2 LSM difference of -30 mmHg in resting LVOT-G (p<0.0001)1 22 LSM difference of -35 mmHg i
Slide 19: MAPLE-HCM: Safety
MAPLE-HCM: Safety Aficamten (n=88) Metoprolol (n=87) Patients with any SAE 7 (8.0) 6 (6.9) Patients with any AE that led to early treatment withdrawal of aficamten or 1 (1.1) 3 (3.4) metoprolola Patients with AE that led to temporary interruption of aficamten or metoprolol 1 (1.1) 1 (1.1) Patients w
Slide 20: Integrated Safety Analysis in oHCM
Integrated Safety Analysis in oHCM Analysis represents nearly 700 patient-years of exposure to aficamten Low incidence of LVEF <50%; no occurrences associated with clinical HF were corroborated by core lab, and all were Safety Events of Interest successfully managed by dose reduction Cumulative af
Slide 21: MYQORZO (aficamten): Commercial Launch
MYQORZO (aficamten) Commercial Launch Prescribing Information Medication Guide 21
Slide 22: Opportunity for CMIs to Treat Symptomatic oHCM Patients
Opportunity for CMIs to Treat Symptomatic oHCM Patients Evolving Understanding of Prevalence Rates for HCM Subtypes: oHCM and nHCM HCM estimated prevalence ~0.3% in the general population ~850k (approximately 1 in 350 individuals)1 Two HCM subtypes: obstructive HCM (oHCM) and nonobstructive HCM
Slide 23: $10B Potential Market of CMI-Eligible Patients
$10B Potential Market of CMI-Eligible Patients Diagnosis of HCM anticipated to grow 5x the rate of the general U.S. population US and EU HCM Patients in 2035 Illustrative 880K1,2 Expected global population of diagnosed patients with Projected Diagnosed HCM Patients oHCM & nHCM (5x the growth rate of
Slide 24: Driving Breadth & Depth Among Concentrated Cardiologist Prescribers
Driving Breadth & Depth Among Concentrated Cardiologist Prescribers HCPs for Personal and Non-Personal Contact Our field team is sized to cover ~10,000 Non-personal promotion HCPs who are treating at least 80% of ~21K Other CMI nonusers oHCM patients among cardiologists Personal promotion At lau
Slide 25: HCP & Patient-Directed Promotional Campaigns Activated
HCP & Patient-Directed Promotional Campaigns Activated For HCPs For Patients HCP Website Office Resources Non-Personal Social Patient Support Patient Website Materials Digital Ads In-Office Patient Materials Email Peer-to-Peer 25
Slide 26: Highly Experienced Sales Team Deployed
Highly Experienced Sales Team Deployed 125 experienced Cardiovascular Account Specialists and Area Business Managers 21 14 4 5 Average years Average years of Average years Average number of industry cardiovascular rare disease of President’s experience experience experience Awards for sales performa
Slide 27: Key Launch Drivers to Achieve High Share and Grow Category
Key Launch Drivers to Achieve High Share and Grow Category Clinical REMS Patient Support Services Flexibility to rapidly titrate as Provide a compliant single point Rapid & sustained early as 2 weeks 1 of contact model that is flexible symptom improvement and and scalable reduction in obstruction
Slide 28: Key Features of REMS Monitoring Schedule
Key Features of REMS Monitoring Schedule for First Year of Therapy Estimated Titration Regimen Across Dose Range MYQORZO CAMZYOS® Process Step 5 mg 10 mg 15 mg 20 mg [within 12 months] Increase dose after Week 12 if Up-titration Increase dose after each echo, Echocardiogram* 3 4 5 6 LVEF ≥55% and Va
Slide 29: MYQORZO & You: Bespoke Treatment Experience
MYQORZO & You : Bespoke Treatment Experience Patient Activation & Engagement Support investigating patient’s health Access & insurance benefits, OOP cost, Prior Reimbursement Authorization and/or Appeal criteria & submission Free drug supply during trial period for Free Trial eligible government-ins
Slide 30: Personal, Timely, Empowering Treatment Experience
Personal, Timely, Empowering Treatment Experience Dedicated single point of contact for patient & HCP creates clarity, continuity, trust throughout treatment journey HCP/Office Experience* Patient Experience MYQORZO & You Navigator Communicates the “how” Dedicated single point of contact for entire
Slide 31: Market Access Strategy
Market Access Strategy Grow CMI class & compete via clinical differentiation, not price CMI Q3 ’25 Payor Mix (TRx) Commercial Pursue comparable access by year-end Goal to reach parity access with coverage criteria consistent with our clinical evidence. Commercial In 2026, plan to: 34% • Continue eng
Slide 32: Measuring Launch Velocity: Key Metrics
Measuring Launch Velocity: 3 Key Metrics Potential to reach >50% share of new patients by the end of 2026 Breadth and depth of HCP Volume of patients prescribing of MYQORZO on MYQORZO Number of HCPs Volume of MYQORZO Volume of patients prescribing MYQORZO prescriptions on MYQORZO each HCP writes HCP
Slide 33: MYQORZO: Encouraging Early Engagement
MYQORZO : Encouraging Early Engagement Early launch metrics signal strong engagement and demand Within first three weeks of drug availability (Jan 26, 2026 – Feb 23, 2026) >12,000 Patients on therapy within first week of Customer engagements, availability reaching over 95% of 700 HCPs who account fo
Slide 34: Precedents for Next-In-Class Success & Category Growth
Precedents for Next-In-Class Success & Category Growth With differentiated product profile, ATTR Class TRx has increased since Attruby Eliquis® generated 1.6x more prescriptions CMI market poised for growth3 launch than Xarelto® Oral anticoagulants Pradaxa® (2010), Xarelto (2011), Eliquis (2012) app
Slide 35: MYQORZO: Advancing Global Availability in 2026
MYQORZO : Advancing Global Availability in 2026 United States Approved by FDA for adults with symptomatic oHCM to improve functional capacity and symptoms LAUNCHED JAN 2026 China Canada Japan New Drug Submission accepted for Phase 3 clinical trials ongoing in Approved by NMPA for adults with NYHA cl
Slide 36: REDWOOD-HCM Cohort 4: Phase 2 Trial in nHCM
REDWOOD-HCM Cohort 4: Phase 2 Trial in nHCM Significant Improvements in KCCQ & NYHA Class 85% of patients achieved 15 mg dose; no discontinuations due to adverse events Kansas City Cardiomyopathy Questionnaire Categorical Changes at Week 10 in KCCQ-CSS NYHA Functional Class Mean improvement in KCCQ
Slide 37: FOREST-HCM: 96-Week Open-Label Data in nHCM
FOREST-HCM: 96-Week Open-Label Data in nHCM Analysis of 34 patients enrolled in FOREST-HCM after REDWOOD-HCM Cohort 4 No early treatment discontinuations, with sustained reductions in symptom burden 79% of patients improved by at least one NYHA Functional Class Mean increase in KCCQ-CSS of 11.
Slide 38: ACACIA-HCM: Pivotal Phase 3 Trial in nHCM
ACACIA-HCM: Pivotal Phase 3 Trial in nHCM Enrollment complete; topline readout expected in Q2 2026 Patients with: Randomization • Trial enrolled over 516 Aficamten End of Study Symptomatic symptomatic nHCM patients N = 420 Screening (1:1) (NYHA Class (EOS) II/III) nHCM, • Dual primary endpoint: chan
Slide 39: Omecamtiv Mecarbil
G Cytokinetics’ Omecamtiv Mecarbil Omecamtiv mecarbil is an investigational agent and has not been approved for use by the U.S. Food & Drug Administration (FDA) or any regulatory agency. The safety and effectiveness of this product have not been established. 39
Slide 40: Omecamtiv Mecarbil: Potential for High-Risk Severe HF Patients Despite GDMT
Omecamtiv Mecarbil: Potential for High-Risk Severe HF Patients Despite GDMT Efficient, pragmatic Phase 3 clinical trial High Unmet Need Ph 3 clinical trial results in 8,000 patients point to important treatment benefit The large and growing heart failure population faces frequent Planning hospitaliz
Slide 41: GALACTIC-HF: Clinical Trial Overview
GALACTIC-HF: Clinical Trial Overview Phase 3 clinical trial Event-driven clinical trial; 8,256 patients randomized in 35 countries at 944 clinical trial sites Chronic HFrEF Patients Randomization 1:1 Currently hospitalized for Omecamtiv mecarbil + Standard HF Therapy End of Study primary reason of H
Slide 42: GALACTIC-HF Primary Composite Endpoint
Primary Composite Endpoint 50 Placebo HR = 0.92 45 (95% CI, 0.86–0.99) 40 Omecamtiv Cumulative incidence, % P = 0.025 mecarbil 35 30 CV Death 25 HR = 1.01 (95% CI, 0.92–1.11) P = 0.86 20 Omecamtiv 15 mecarbil 10 5 0 0 6 12 18 24 30 36 Patients Months (30 days) since randomization at risk, n Placebo
Slide 43: Benefit Observed to Increase as Baseline LVEF Decreased
Benefit Observed to Increase as Baseline LVEF Decreased Incidence of Primary Composite Endpoint Relative Treatment Effect on Primary Endpoint 60 50 Placebo 1.2 Incidence Rate (per 100 py) 40 Treatment Effect (Ratio) Treatment 1.0 Effect 30 Omecamtiv 0.8 mecarbil 20 0.6 4,456 patients 3,776 patients
Slide 44: Large Treatment Effect in Easily Defined HF Population
Large Treatment Effect in Easily Defined HF Population Nom N Hazard Ratio (95% CI) ARR p-value All Patients 8232 0.025 2.1 LVEF <30% 4704 <0.001 4.9 + Hosp <3 mos 2836 <0.001 6.2 + SBP <110 1881 0.004 7.2 + Class III/IV 2249 <0.001 8.9 + NT-proBNP ≥1000 pg/mL 2852 <0.001 8.8 0.6 0.7 0.8 0.9 1 1.1 1.
Slide 45: Phase 3 Confirmatory Clinical Trial Design: COMET-HF
Phase 3 Confirmatory Clinical Trial Design Currently enrolling COMET-HF: Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure 2-week washout period LVEF < 30% 2-week run-in period • Primary endpoint: time to within 6 mo Omecamtiv Mecarbil + Standard of Care CV death, HF events, Direct
Slide 46: Large and Growing Target Patient Population in US
Large and Growing Target Patient Population in US Prevalence in Adults (18+, USA) 2020 Estimates 2029 Estimates 7.1M1 8.6M3 Heart Failure Including HFpEF 3.5M2 4.3M3 HFrEF Population 2.4M2 2.8M3 HFrEF Patients with EF<30% ~720K4 ~840K4 High risk HF patients with EF<30% Proposed Cardiac Function Mark
Slide 47: Higher Event Rate & Costs in Patients with Severely Reduced EF
Higher Event Rate & Costs in Patients with Severely Reduced EF Accounts for ~60% of HFrEF hospitalizations5 35% of patients with severely reduced EF re-hospitalized within 1 year6 $15,493 per HF re-hospitalization7 Direct costs from HF re-hospitalizations projected to increase from $3.9 billion in 2
Slide 48: Ulacamten (CK-586)
G Cytokinetics’ Ulacamten (CK-586) Ulacamten is an investigational agent and has not been approved for use by the U.S. Food & Drug Administration (FDA) or ar regulatory agency. The safety and effectiveness of this product have not been established. 48
Slide 49: Heart Failure with Preserved Ejection Fraction (HFpEF)
Heart Failure with Preserved Ejection Fraction (HFpEF) Despite broad use of standard treatments & advances in care, the prognosis for patients with HF is poor1 ~75% ~84% HFpEF patients will HFpEF patients will Subset of HFpEF patients Significant increase Lifetime healthcare costs die within five ye
Slide 50: Ulacamten: Distinct Mechanism of Action from Aficamten
Ulacamten: Distinct Mechanism of Action from Aficamten “Fewer hands pulling on the rope” Before Ulacamten After Ulacamten Ulacamten Mechanochemical domain ATP Post-Powerstroke State Actin sliding Actin sliding Ulacamten is an investigational drug and is not approved by any regulatory agency. Its saf
Slide 51: Ulacamten: Shallow In Vivo Concentration-Response
Ulacamten: Shallow In Vivo Concentration-Response Ulacamten has a shorter half-life than aficamten Pharmacodynamic window Fractional shortening IC50 /IC10 ratio mavacamten 2.8x aficamten 9.9x ulacamten 9.3x IC10: plasma concentration at 10% relative reduction in fractional shortening IC50: plasma co
Slide 52: Phase 1 Data Support Advancement to Phase 2 Clinical Trial
Phase 1 Data Support Advancement to Phase 2 Clinical Trial Phase 1 study design: 7 SAD cohorts (10 mg to 600 mg) & 2 MAD cohorts (100 & Change in LVEF vs. 200 mg once daily), 10 participants each Plasma Concentration Ulacamten Plasma (mean [SD]) over time after single ascending doses of ulacamten Co
Slide 53: Phase 2 Study Schema: AMBER-HFpEF
Phase 2 Study Schema Currently enrolling AMBER-HFpEF: Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF 6 WEEKS 6 WEEKS 2 weeks 1 Enrolling HFpEF SoC + Placebo Cohort 1 patients with: n=12 Washout SoC + 150 mg ulacamten SoC + 300 mg ulacamten • LV
Slide 54: Ulacamten: Focusing on Patients with HFpEF and EF ≥60%
Ulacamten: Focusing on Patients with HFpEF and EF ≥ 60 7.9M 4.0M (2024) 1.0M (EF>65) to 2.0M (EF > 60) Heart Failure Prevalence in 2024, US 50% of HF with HFpEF (EF ≥ 50%) ~20% of HF with EF ≥ 60% 2024 prevalence calculated using published, historic estimate and projected to 2024 using age adjusted
Slide 55: Ulacamten May Address Unmet Needs of HFpEF Patients
Ulacamten May Address Unmet Needs of HFpEF Patients Proposed Mechanistic Benefits Target Product Profile • Statistically significant reduction in composite of mortality and • Ulacamten may benefit cardiac relaxation hospitalization outcomes during diastole • Oral QD tablet • Ulacamten may reduce sym
Slide 56: Financials & Milestones
Cytokinetics’ ——)EMhi iéaé sé&BdM SS Financials & Milestones
Slide 57: Strong Financial Position
Strong Financial Position Well-capitalized to execute launch & advance R&D pipeline ~$1.2B in cash, cash equivalents and investments as of December 31, 2025 Further access to capital Proceeds of $100M from Tranche 5 loan received in October 2025 through term loans with Royalty Pharma (RP) Eligible t
Slide 58: 2026 Financial Guidance
2026 Financial Guidance Guidance Issued on Feb. 24, 2026 GAAP Combined R&D and SG&A Expense $830M to $870M Non-cash stock-based compensation expense included in $130M to $120M GAAP Combined R&D and SG&A Expense The financial guidance does not include: 1) collaboration expenses which can include reim
Slide 59: 2026 Expected Milestones
2026 Expected Milestones Omecamtiv Mecarbil Ulacamten Launch MYQORZO in Germany in Q2 2026 Complete enrollment in Report topline results from ACACIA-HCM in Q2 2026 Cohort 1 of AMBER-HFpEF Potential FDA decision on the Continue enrollment in in Q1 2026 sNDA for MAPLE-HCM in Q4 2026 COMET-HF through 2
Slide 60: Thank You
THANK YOU 60